The negative impact of HBV/HCV coinfection on cirrhosis and its consequences von Pol, S., Haour, G., Fontaine, H., Dorival, C., Petrov‐Sanchez, V., Bourliere, M., Capeau, J., Carrieri, P., Larrey, D., Larsen, C., Marcellin, P., Pawlostky, J.‐M., Nahon, P., Zoulim, F., Cacoub, P., Ledinghen, V., Mathurin, P., Negro, F., Pageaux, G.‐P., Yazdanpanah, Y., Wittkop, L., Zarski, J.‐P., Carrat, F.

Volltext

Standardization of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers Based on Prevalences of Fibrosis Stages von Poynard, Thierry, Halfon, Philippe, Castera, Laurent, Munteanu, Mona, Imbert-Bismut, Francoise, Ratziu, Vlad, Benhamou, Yves, Bourliere, Marc, de Ledinghen, Victor, FibroPaca Group

Volltext

The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non‐invasive fibrosis biomarkers: an international study of 2411 cases von Sebastiani, G., Castera, L., Halfon, P., Pol, S., Mangia, A., Di Marco, V., Pirisi, M., Voiculescu, M., Bourliere, M., Alberti, A.

Volltext

The accuracy of the FIB‐4 index for the diagnosis of mild fibrosis in chronic hepatitis B von MALLET, V., DHALLUIN‐VENIER, V., ROUSSIN, C., BOURLIERE, M., PETTINELLI, M. E., GIRY, C., VALLET‐PICHARD, A., FONTAINE, H., POL, S.

Volltext

Hepatitis C therapy in non-genotype 1 patients: the near future von Wartelle-Bladou, C., Le Folgoc, G., Bourlière, M., Lecomte, L.

Volltext

Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data von Asselah, T., Lampertico, P., Aleman, S., Bourliere, M., Streinu-Cercel, A., Bogomolov, P., Morozov, V., Stepanova, T., Lazar, S., Suri, V., Manuilov, D., Mercier, R.C., Tseng, S., Ye, L., Flaherty, J.F., Osinusi, A., Brunetto, M., Wedemeyer, H.

Volltext

Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B von Peters, Marion G, Hann Hw, H w, Martin, Paul, Heathcote, E Jenny, Buggisch, P, Rubin, R, Bourliere, M, Kowdley, K, Trepo, C, Gray Df, D f, Sullivan, M, Kleber, K, Ebrahimi, R, Xiong, S, Brosgart, Carol L

Volltext

A national survey of acute hepatitis E in France von RENOU, C., MOREAU, X., PARIENTE, A., CADRANEL, J.‐F., MARINGE, E., MORIN, T., CAUSSE, X., PAYEN, J.‐L., IZOPET, J., NICAND, E., BOURLIÈRE, M., PENARANDA, G., HARDWIGSEN, J., GEROLAMI, R., PÉRON, J.‐M., PAVIO, N.

Volltext

Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation von POYNARD, T., HALFON, P., CASTERA, L., CHARLOTTE, F., BAIL, B. LE, MUNTEANU, M., MESSOUS, D., RATZIU, V., BENHAMOU, Y., BOURLIÈRE, M., LEDINGHEN, V. DE

Volltext

RNA editing blood biomarkers for predicting mood alterations in HCV patients von Salvetat, N., Van der Laan, S., Vire, B., Chimienti, F., Cleophax, S., Bronowicki, J. P., Doffoel, M., Bourlière, M., Schwan, R., Lang, J. P., Pujol, J. F., Weissmann, D.

Volltext

Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C von Sebastiani, G., Halfon, P., Castera, L., Mangia, A., Di Marco, V., Pirisi, M., Voiculescu, M., Bourliere, M., Alberti, A.

Volltext

Les hépatopathies cholestastiques chroniques von BOURLIERE, M

Volltext

P0856 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has mild impact on Health-Related Quality of Life (HRQoL) compared with placebo during 12-week treatmen... von Liu, Y, Larsen, L, Bourliere, M, Baran, R, Juday, T

Volltext

P.09.14: Magnitude of Liver Stiffness Regression after Achieving Sustained Virologic Response in Patients with Chronic Hepatitis C: A Meta-Analysis von Facciorusso, A, Singh, S, Del Prete, V, Bourliere, M, Loomba, R, Muscatiello, N

Volltext

Impact of common risk factors of fibrosis progression in chronic hepatitis C von Rüeger, S, Bochud, P-Y, Dufour, J-F, Müllhaupt, B, Semela, D, Heim, M H, Moradpour, D, Cerny, A, Malinverni, R, Booth, D R, Suppiah, V, George, J, Argiro, L, Halfon, P, Bourlière, M, Talal, A H, Jacobson, I M, Patin, E, Nalpas, B, Poynard, T, Pol, S, Abel, L, Kutalik, Z, Negro, F

Volltext

Sustained viral response following treatment with direct acting antiviral agents for chronic hepatitis C and the risk of hepatocellular carcinoma von Reddy, K.R, Bourliere, M, Agarwal, K, Lawitz, E, Osinusi, A, Kersey, K, Crans, G, Moody, S, Ni, L, Brainard, D.M, McHutchison, J.G, Muir, A.J, Buti, M

Volltext

Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin von Foster, G. R., Ferenci, P., Asselah, T., Mantry, P., Dufour, J.-F., Bourlière, M., Forton, D., Maevskaya, M., Wright, D., Yoshida, E. M., García-Samaniego, J., Oliveira, C., Wright, M., Warner, N., Sha, N., Quinson, A.-M., Stern, J. O.

Volltext

High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or w... von Younossi, Z.M, Stepanova, M, Jacobson, I, Zeuzem, S, Bourliere, M, Foster, G, Roberts, S, Asselah, T, Thompson, A, Gane, E, Willems, B, Lawitz, E, Gordon, S, Mann, M, Reddy, K.R, Cooper, C, Flamm, S, Kowdley, K, Hunt, S

Volltext

Retreatment of hepatitis C virus daa failures in real life: easy and difficult to cure patients von Ouzan, D, Penaranda, G, Lefolgoc, G, Antoni, M, Delasalle, P, Fontanges, T, Cerdan, P, Toulemonde, P, Bresson-Hadni, S, Beorchia, S, Boyer, N, Hanslik, B, Joly, H, Liautard, J, Baesjou, S, Bonny, C, Halfon, P, Renou, C, Bourliere, M

Volltext

Retreatment with Direct Active Antivirals of genotype 1, 3 and 4 chronic hepatitis C patients who previously failed an anti-NS5A-containing regimen in real world von Halfon, P, Scholtes, C, Izopet, J, Larrat, S, Penaranda, G, Trimoulet, P, Zoulim, F, Alric, L, Metivier, S, Bourliere, M, Leroy, V, Ouzan, D, de Ledinghen, V, Mohamed, S, Thelu, M.-A, Abravanel, F

Volltext